Improved Detection of HIV-2 DNA in Clinical Samples Using a Nested Primer-Based Polymerase Chain Reaction

Grankvist, Olov; Bredberg-Rådén, Ulla; Gustafsson, Åke; Albert, Jan; Albino, Paulo; Pa, Andreasson; Nauclér, Anders; Biberfeld, Gunnel; Wadell, Göran

doi:10.1097/00126334-199203000-00010

Cited by 29 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DNA templates were derived by amplifying a region of the gag gene of the HIV-2 plasmid pGH123 [30] with the primers OG53 and OG106 [31]. The resulting PCR product was cloned into pCRII (Invitrogen, Carlsbad, CA), forming a standard (STD) template.…”

Section: Methodsmentioning

confidence: 99%

Lower Human Immunodeficiency Virus (HIV) Type 2 Viral Load Reflects the Difference in Pathogenicity of HIV‐1 and HIV‐2

Popper

Sarr²,

Travers³

et al. 1999

J INFECT DIS

211

131

View full text Add to dashboard Cite

Human immunodeficiency virus type 2 (HIV-2) is less pathogenic than HIV type 1 (HIV-1), but the mechanisms underlying this difference have not been defined. We developed an internally controlled quantitative reverse transcriptase-polymerase chain reaction to measure HIV-2 viral load and determined levels of plasma virus in a cohort of registered commercial sex workers in Dakar, Senegal. The assay has a lower limit of detection of 100 copies/mL and is linear over 4 logs. HIV-2 viral RNA was detectable in 56% of all samples tested; the median load was 141 copies/mL. Levels of viral RNA in the plasma were inversely related to CD4+ cell counts. HIV-2 and HIV-1 viral loads were compared among the seroincident women in the cohort; the median viral load was 30x lower in the HIV-2-infected women (P<.001, Wilcoxon rank sum test), irrespective of the length of time infected. This suggests that plasma viremia is linked to the differences in the pathogenicity of the 2 viruses.

show abstract

Section: Methodsmentioning

confidence: 99%

Lower Human Immunodeficiency Virus (HIV) Type 2 Viral Load Reflects the Difference in Pathogenicity of HIV‐1 and HIV‐2

Popper

Sarr²,

Travers³

et al. 1999

J INFECT DIS

211

131

View full text Add to dashboard Cite

show abstract

“…RNA was amplified by a one-step procedure using a Titan one-tube RT-PCR kit (Roche) with primers located in the gag region (GAG OG S1 and GAG OG AS1). Amplified products were subjected to nested PCR with primers GAG OG S2 and GAG OG AS2 as previously described (16,19). The efficiency and sensitivity of qualitative reverse transcription-PCR for detection of viral RNA isolated from plasma were determined by using a transcript standard diluted in 200 l of RPMI medium to obtain 5,000, 1,000, 500, and 250 copies (seven replicates each).…”

Section: Methodsmentioning

confidence: 99%

Quantification of Proviral Load of Human Immunodeficiency Virus Type 2 Subtypes A and B Using Real-Time PCR

et al. 2001

View full text Add to dashboard Cite

“…In cases in which serological testing could not positively distinguish the infecting virus, confirmation was performed by diagnostic PCR for HIV-1 and HIV-2, as previously described [15,16]. Diagnostic PCR was performed on PBMC-derived DNA.…”

mentioning

confidence: 99%

Highly Active Antiretroviral Therapy and Viral Response in HIV Type 2 Infection

Mullins

Eisen

Popper

et al. 2004

Clinical Infectious Diseases

View full text Add to dashboard Cite

Improved Detection of HIV-2 DNA in Clinical Samples Using a Nested Primer-Based Polymerase Chain Reaction

Cited by 29 publications

References 0 publications

Lower Human Immunodeficiency Virus (HIV) Type 2 Viral Load Reflects the Difference in Pathogenicity of HIV‐1 and HIV‐2

Lower Human Immunodeficiency Virus (HIV) Type 2 Viral Load Reflects the Difference in Pathogenicity of HIV‐1 and HIV‐2

Quantification of Proviral Load of Human Immunodeficiency Virus Type 2 Subtypes A and B Using Real-Time PCR

Highly Active Antiretroviral Therapy and Viral Response in HIV Type 2 Infection

Contact Info

Product

Resources

About